# Nabsys

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nabsys

- Industry: Biotechnology
- Headquarters: Providence, US
- Website: www.nabsys.com
- Total disclosed funding: $80M
- Latest round: Series E (Aug 21, 2014)
- Investors on record: 4

## About

Nabsys specializes in electronic genome mapping technology, providing advanced tools for genomic analysis. Their innovative solutions enhance the understanding of genetic variation and support research in genomics and molecular biology.Founded in 2004 by Barrett Bready, Nabsys operates from its headquarters in Providence, US, focusing on advanced genomic analysis. The company has successfully raised funding in 11 deals, with the most recent being a Series B round in August 2024, amounting to USD 13.00 mn, led by Hitachi High-Tech Corporation. Notably, Nabsys has pivoted towards enhancing its molecular diagnostics business, aligning with its product development strategy.Nabsys offers a sophisticated electronic genome mapping platform designed to provide comprehensive insights into the human genome. The company's core product, the OhmX Analyzer, serves as a benchtop solution for detecting structural variants (SVs) at the whole genome level, enabling researchers to access critical genomic data with high sensitivity and accuracy. Additionally, Nabsys has developed the Human Chromosome Explorer™ (HCE) in collaboration with Hitachi High Tech, which comprises a suite of secondary analytical software tools that facilitate genome assembly and SV identification tailored to specific research parameters. These products are primarily targeted at academic and clinical laboratories engaged in genomic research, particularly in the United States, Canada, Europe, and select regions in Asia. By focusing on the analysis of SVs, which constitute over 1% of the human genome, Nabsys aims to enhance the understanding of genetic disorders, cancer research, and other areas of functional genomics.Nabsys generates revenue through its direct sales model, offering products such as the OhmX Analyzer and the Human Chromosome Explorer to laboratories engaged in genomic research. The transaction structure typically involves B2B partnerships with academic institutions, research facilities, and clinical laboratories, where customers purchase the analytical tools to perform high-resolution genomic analyses. Nabsys provides training and support alongside its products, creating an integrated service offering that enhances customer satisfaction and retention. Pricing plans are structured around the procurement of devices, software licenses, and potential service contracts, ensuring that clients receive comprehensive support tailored to their research needs. By focusing on high-value, specialized products aimed at advancing genomic research, Nabsys positions itself within a niche market that caters to professionals in genomics and molecular biology.Following the recent Series B funding in August 2024, Nabsys plans to accelerate the launch of genome map-related businesses and strengthen its molecular diagnostics operations. The funding will facilitate the introduction of new products aimed at enhancing genomic research capabilities. Nabsys is also targeting expansion into additional geographic markets, focusing on regions in Asia and Europe by 2025.

## Funding rounds

- Series E, Aug 21, 2014, $26M — Bay City Capital
- Series D, Mar 1, 2013, $35M — Stata Venture Partners, Bay City Capital, PJC
- Series C, Sep 14, 2011, $10M — Stata Venture Partners
- Series B, Feb 9, 2010, $7M — Stata Venture Partners, PJC
- Series A, May 6, 2009, $1.8M — PJC, Slater Technology Fund
- Seed, Jun 7, 2005, $0.2M — Slater Technology Fund

## Investors

- Slater Technology Fund (https://capitalatlas.ai/funds/slater-technology-fund) — Seed, Series A
- PJC (https://capitalatlas.ai/funds/pjc) — Series A, Series B, Series D
- Stata Venture Partners (https://capitalatlas.ai/funds/stata-venture-partners) — Series B, Series C, Series D
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series D, Series E